Drug Trial Radar · NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
366
Planned (sponsor's estimate)
Start
Jan 4, 2023
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Marengo Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.
Conditions
- Advanced Solid Tumors
- Genital Neoplasm, Female
- Urogenital Neoplasms
- Lung Neoplasm
- Neoplasms by Site
- Papillomavirus Infection
- Epstein-Barr Virus Infections
- Carcinoma
- Neoplasms
- Vulvar Neoplasms
- Vulvar Diseases
- Abdominal Neoplasm
- NSCLC (Non-small Cell Lung Cancer)
- Colorectal Cancer
Interventions
STAR0602Drug
solution, intravenous infusion
Irinotecan (Camptosar)Combination product
solution, intravenous infusion
Docetaxel (Taxotere)Combination product
solution, intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1Time frame: Cycle 1 (Cycle length= 28 days)
- Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 3 years
- Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)Time frame: Up to 3 years
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
UC Davis Comprehensive Cancer Center
Sacramento, California · Active not recruiting
AdventHealth Celebration
Celebration, Florida · Recruiting
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida · Active not recruiting
The University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
National Institutes of Health
Bethesda, Maryland · Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville)
Nashville, Tennessee · Recruiting
The University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
UT Health Mays Cancer Center
San Antonio, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Active not recruiting
University of Wisconsin- Madison
Madison, Wisconsin · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Institute Gustave Roussy
Villejuif, France · Recruiting
START Madrid FJD
Madrid, Spain · Recruiting
Instituto de Investigacion Sanitaria, INCLIVA
Valencia, Spain · Recruiting
Vall d'Hebron Institute of Oncology
Barcelona, Catalonia, Spain · Recruiting
Hospital Universitario Quirónsalud Madrid
Madrid, Spain, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.